Transce3nd’s Insight Molecular Diagnostics IMDX Stock Holding History

Transce3nd’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.02K	Buy	+1,000	New	+$4.43K	﹤0.01%	459

Other funds holding IMDX

Family Office Research Bethesda, Maryland $260M AUM 20.53% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

Zevenbergen Capital Investments Edmonds, Washington $4.37B AUM 52.9% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Piscataqua Savings Bank Portsmouth, New Hampshire $146M AUM 24.42% 1-Year Est. Return

Albion Financial Group Salt Lake City, Utah $1.77B AUM 14.95% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Transce3nd's IMDX Position: Q3 2026 in Review

Transce3nd opened a new position in Insight Molecular Diagnostics (IMDX) in Q3 2026: 1,000 shares worth $3.02K. The stake represents ﹤0.01% of the portfolio and ranks #459 among its holdings.

9 funds tracked by Wall St. Rank hold IMDX as of Q3 2026.

Transce3nd held 1,000 shares of Insight Molecular Diagnostics worth $3.02K as of Q3 2026.
Insight Molecular Diagnostics was a new Transce3nd position in Q3 2026.
Insight Molecular Diagnostics made up ﹤0.01% of Transce3nd's portfolio in Q3 2026, its #459 holding.
9 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2026.

Based on Transce3nd's 13F filing for Q3 2026, filed 26 Oct 2026.